At the TIPS journal club meeting held on April 08, 2019, a topic of “Block buster drugs 2018’’ was presented by R. Farhadi. A brief summary of this presentation is in below.
2018 is set to be an exciting year that will see valuable additions to existing treatments as well as disruptions to certain markets. By 2022, three drugs are forecast to exceed annual revenue of more than $3 billion, while nine additional drugs are forecast to generate annual sales of between $1 billion and $2 billion. As the drug-pricing debate continues in 2017 a record of 46 new drug approvals by the Food and Drug Administration (FDA) is published which is the highest total in more than two decades. Of these approved drugs, 17 (37%) were approved with breakthrough therapy designation, a designation created in 2012 to accelerate the development of products that showed substantial improvement over existing therapies for serious and life-threatening diseases. The approval of cancer immunotherapies) and chimeric antigen receptor T cell (CAR-T) therapies grabbed headlines in 2017 because of their ability to revolutionize the treatment of the disease. These therapies, a form of gene therapy, represent a major breakthrough for the development of personalized medicine and lay the groundwork for further advances in this field.